These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8067772)

  • 21. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.
    Mouton JW; Vinks AA; Punt NC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):733-8. PubMed ID: 9087479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 May; 49(5):445-52. PubMed ID: 10792202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
    Cappelletty DM
    Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis.
    Bosso JA; Bonapace CR; Flume PA; White RL
    Pharmacotherapy; 1999 May; 19(5):620-6. PubMed ID: 10331825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase.
    Bagge N; Ciofu O; Skovgaard LT; Høiby N
    APMIS; 2000 Sep; 108(9):589-600. PubMed ID: 11110047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
    Mouton JW; Horrevorts AM; Mulder PG; Prens EP; Michel MF
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2307-11. PubMed ID: 2088186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
    Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
    Leegwater E; Wewerinke L; de Grauw AM; van Veen M; Storm BN; Kruizinga MD
    Clin Pharmacokinet; 2023 May; 62(5):715-724. PubMed ID: 36972008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
    den Hollander JG; Mouton JW; Verbrugh HA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth curves of Escherichia coli and Pseudomonas aeruginosa submitted to different ceftazidime concentrations.
    Yourassowsky E; Van der Linden MP; Lismont ML; Crokaert F
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():127-30. PubMed ID: 19802976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrolysis of cefazolin by enzymes produced by Pseudomonas aeruginosa after exposure to ceftazidime in vitro.
    Papaioannidou P; Nitsas V; Mirtsou-Fidani V
    Vojnosanit Pregl; 2009 Oct; 66(10):785-90. PubMed ID: 19938755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Pea F; Viale P; Damiani D; Pavan F; Cristini F; Fanin R; Furlanut M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.